Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.34 |
| ▸ | PDE6D | O43924 | 1/20 | 0.34 |
| ▸ | PDE6A | P16499 | 1/20 | 0.34 |
| ▸ | PDE6G | P18545 | 1/20 | 0.34 |
| ▸ | PDE6B | P35913 | 1/20 | 0.34 |
| ▸ | PDE6C | P51160 | 1/20 | 0.34 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27074710 | 1.00 | IRAK4 (0.35) | IRAK4LRRK2PDE6DPDE6APDE6G | |
| SCHEMBL27074802 | 0.79 | LRRK2 (0.35) | LRRK2PDE6DPDE6APDE6GPDE6B | |
| SCHEMBL30729191 | 0.79 | LRRK2 (0.35) | LRRK2PDE6DPDE6APDE6GPDE6B | |
| SCHEMBL27074906 | 0.73 | PDE10A (0.38) | IRAK4LRRK2PDE6DPDE6APDE6G | |
| SCHEMBL27074696 | 0.73 | PDE10A (0.38) | IRAK4LRRK2PDE6DPDE6APDE6G | |
| SCHEMBL27074745 | 0.72 | PDE10A (0.37) | IRAK4LRRK2PDE6DPDE6APDE6G | |
| SCHEMBL27075031 | 0.70 | PDE6D (0.37) | LRRK2PDE6DPDE6APDE6GPDE6B | |
| SCHEMBL30729184 | 0.70 | PDE6D (0.37) | LRRK2PDE6DPDE6APDE6GPDE6B | |
| SCHEMBL27074723 | 0.68 | PDE6D (0.38) | IRAK4LRRK2PDE6DPDE6APDE6G | |
| SCHEMBL3766783 | 0.67 | LRRK2 (0.54) | IRAK4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | IRAK4 3981/4885LRRK2 4153/4885PDE6D 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.